1. Home
  2. SVAQ vs VCRE Comparison

SVAQ vs VCRE Comparison

Compare SVAQ & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silicon Valley Acquisition Corp. Class A Ordinary Shares

SVAQ

Silicon Valley Acquisition Corp. Class A Ordinary Shares

N/A

Current Price

$10.07

Market Cap

295.0M

Sector

Finance

ML Signal

N/A

Logo Vicore Pharma Holding AB American Depositary Shares

VCRE

Vicore Pharma Holding AB American Depositary Shares

N/A

Current Price

$10.78

Market Cap

316.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SVAQ
VCRE
Founded
2025
N/A
Country
United States
Sweden
Employees
N/A
N/A
Industry
Blank Checks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
295.0M
316.4M
IPO Year
2025
2026

Fundamental Metrics

Financial Performance
Metric
SVAQ
VCRE
Price
$10.07
$10.78
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
25.2K
8.0K
Earning Date
01-01-0001
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.86
$10.47
52 Week High
$10.16
$13.15

Technical Indicators

Market Signals
Indicator
SVAQ
VCRE
Relative Strength Index (RSI) 62.80 43.48
Support Level $10.00 $10.75
Resistance Level $10.12 $13.00
Average True Range (ATR) 0.02 0.57
MACD 0.00 -0.02
Stochastic Oscillator 41.18 25.75

Price Performance

Historical Comparison
SVAQ
VCRE

About SVAQ Silicon Valley Acquisition Corp. Class A Ordinary Shares

Silicon Valley Acquisition Corp is a blank check company.

About VCRE Vicore Pharma Holding AB American Depositary Shares

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.

Share on Social Networks: